COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA IN CANADA

被引：0
|
作者：
Lachaine, J. [1 ]
Beauchemin, C. [1 ]
Mathurin, K. [1 ]
Aissa, F. [2 ]
机构：
[1] Univ Montreal, Montreal, PQ, Canada
[2] Lundbeck Canada Inc, Montreal, PQ, Canada
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A141 / A142
页数：2
相关论文
共 50 条
  • [31] GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Sehn, Laurie Helen
    Chua, Neil Sun
    Mayer, Jiri
    Dueck, Gregory Scott
    Trnen, Marek
    Bouabdallah, Kamal
    Fowler, Nathan Hale
    Delwail, Vincent
    Press, Oliver W.
    Salles, Gilles A.
    Gribben, John G.
    Lennard, Anne
    Lugtenburg, Pieternella J.
    Franklin, Natalie
    Fritsch, Elisabeth Wassner
    Fingerle-Rowson, Guenter
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    McKinney, Matthew S.
    Beaven, Anne W.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 45 - 59
  • [33] Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
    Bruce D. Cheson
    Peter C. Trask
    John G. Gribben
    Natalie Dimier
    Eva Kimby
    Pieternella J. Lugtenburg
    Catherine Thieblemont
    Elisabeth Wassner-Fritsch
    Aino Launonen
    Laurie H. Sehn
    Annals of Hematology, 2017, 96 : 253 - 259
  • [34] Zevalin - Ibritumomab tiuxetan - IDEC - Radiommunotherapeutic for non-Hodgkin's lymphoma
    不详
    FORMULARY, 2002, 37 (04) : 170 - 170
  • [35] Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
    Cheson, Bruce D.
    Trask, Peter C.
    Gribben, John G.
    Dimier, Natalie
    Kimby, Eva
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wassner-Fritsch, Elisabeth
    Launonen, Aino
    Sehn, Laurie H.
    ANNALS OF HEMATOLOGY, 2017, 96 (02) : 253 - 259
  • [36] A phase II study of single-agent bendamustine in rituximab-refractory B-cell non-Hodgkin's lymphoma
    Forero-Torres, Andres
    Cohen, Philip
    Cheson, Bruce D.
    Robinson, K. Sue
    La Casce, Ann S.
    Fayad, Luis
    Camacho, Elber S.
    Williams, Michael E.
    van der Jagt, Richard H.
    Friedberg, Jonathan W.
    ANNALS OF ONCOLOGY, 2006, 17 : 203 - 203
  • [37] Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Coutre, Steven E.
    Flinn, Ian W.
    Schreeder, Marshall T.
    Fowler, Nathan H.
    Sharman, Jeff P.
    Boccia, Ralph V.
    Barrientos, Jacqueline C.
    Rai, Kanti R.
    Boyd, Thomas E.
    Furman, Richard R.
    Kim, Yeonhee
    Godfrey, Wayne R.
    Leonard, John P.
    BLOOD ADVANCES, 2016, 1 (02) : 122 - 131
  • [38] Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia
    Elefante, Anjana
    Czuczman, Myron S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (09) : 713 - 723
  • [39] Rituximab therapy for indolent non-Hodgkin's lymphoma
    Hagenbeek, A
    Czuczman, MS
    Ghielmini, M
    Herold, M
    Kimby, E
    Solal-Céligny, P
    Unterhalt, M
    ANTI-CANCER DRUGS, 2002, 13 : S11 - S17
  • [40] Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    ANNALS OF ONCOLOGY, 2006, 17 : 200 - 200
12345